1 Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is

2 associated with faster viral clearance and COVID-19 symptom resolution.

- 3 Nora Pisanic¹, Annukka A. R. Antar², Marissa K. Hetrich³, Zoe O. Demko², Xueyan Zhang³, Kristoffer
- 4 Spicer¹, Kate L. Kruczynski¹, Barbara Detrick⁴, William Clarke⁴, Maria Deloria Knoll³, David L. Thomas^{2,4},
- 5 Fatimah S. Dawood⁵, Vic Veguilla⁵, Ruth A. Karron³, Yukari C. Manabe^{2,3,7}, Christopher D. Heaney^{1,3,6}

6 Affiliations

- 7 ¹Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns
- 8 Hopkins University, Baltimore, Maryland, USA
- 9 ²Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University,
- 10 Baltimore, Maryland, USA
- ³Department of International Health, Bloomberg School of Public Health, Johns Hopkins University,
- 12 Baltimore, Maryland, USA
- ⁴Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
- ⁵COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- ⁶Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore,
 Maryland, USA
- ¹⁷ ⁷Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns
- 18 Hopkins University, Baltimore, Maryland, USA
- 19
- 20 Corresponding author: Christopher D. Heaney, Department of Environmental Health and Engineering,
- 21 Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., W7033B, Baltimore, MD USA, E-
- 22 mail: <u>cheaney1@jhu.edu</u> Phone: (443) 287-4989
- 23
- 24 Keywords
- 25 SARS-CoV-2, COVID-19, mucosal immunity, oral fluid, intranasal vaccines, multiplex, long COVID, PACS
- 26
- 27 Disclaimer
- 28 The findings and conclusions in this report are those of the authors and do not necessarily represent the
- 29 official position of the Centers for Disease Control and Prevention.

30

31 Abstract

- High priority efforts are under way to support the development of novel mucosal COVID-19 vaccines,
- 33 such as the US Government's Project NextGen and the Center for Epidemic Preparedness Innovations'
- 34 (CEPI) goal to respond to the next pandemic with a new vaccine in 100 days. However, there is limited
- 35 consensus about the complementary role of mucosal immunity in disease progression and how the
- 36 immunogenicity of mucosal vaccines will be evaluated. This study investigated the role of oral mucosal
- antibody responses in viral clearance and in COVID-19 symptom duration.
- 38 Participants with PCR-confirmed SARS-CoV-2 infection provided oral fluid for testing with SARS-CoV-2
- antibody multiplex assays, nasal swabs for RT-PCR and symptom information at up to eight follow-ups
 from April 2020 to February 2022.
- 41 High and moderate oral fluid anti-spike (S) SIgA post infection was associated with significantly higher
- 42 likelihood of viral clearance and of COVID-19 symptom resolution across age groups. Those with high
- 43 and moderate anti-S SIgA cleared the virus and recovered 14 days (95% CI: 10-18 days) and 9-10 days
- 44 (95% CI: 6-14 days) earlier, respectively. Delayed but higher oral fluid anti-S IgG was associated with
- 45 significantly longer time to viral clearance and recovery. The effect size of moderate or high SIgA was
- 46 equivalent to prior COVID-19 vaccine immunity, which was also associated with faster clearance and
- 47 recovery. Unvaccinated adults with prolonged COVID-19 symptoms had significantly lower anti-RBD SIgA
- 48 15-30 days after infection onset (*p*<0.001).
- 49 Robust mucosal SIgA early post infection appears to support faster clearance of SARS-CoV-2 and
- 50 recovery from COVID-19 symptoms. This research underscores the importance of harmonizing mucosal
- 51 immune response assays to evaluate new vaccines that can boost local mucosal immunity.

52 Introduction

- 53 While COVID-19 vaccines have saved millions of lives in the US, they have not stopped SARS-CoV-2
- 54 breakthrough infections or transmission of ever evolving variants. Despite triple vaccination, multiple
- 55 studies have shown that breakthrough SARS-CoV-2 infections are common with the rapidly evolving
- 56 omicron variants. (1,2) Currently approved intramuscular COVID-19 vaccines elicit strong serum
- 57 neutralizing antibody (nAb) titers and binding IgG to SARS-CoV-2 spike protein (S), which have been
- identified as correlates of protection from symptomatic and severe COVID-19, however, they confer
- 59 little mucosal immunity at the site of virus entry.(3) Blood nAb titers and anti-S IgG levels decline within
- 60 months, resulting in the need for multiple intramuscular boosters with updated composition to match
- 61 circulating variants. To break this continuing infection and transmission cycle, novel mucosal vaccines
- are being developed with support of national and international programs, such as the US government's
- 63 Project NextGen and the Center for Epidemic Preparedness Innovations (CEPI) with the goal to respond
- to the next pandemic with a new vaccine in 100 days.(4)
- 65 Mucosal SARS-CoV-2 anti-S IgA was observed to be a correlate for prevention of omicron infection as
- 66 determined by positive polymerase chain reaction (PCR) results for viral RNA in triple-vaccinated health
- 67 care workers. (5) Early in the COVID-19 pandemic, higher anti-RBD antibody levels in nasal mucosal lining
- 68 fluid were shown to be associated with lower viral loads after PCR-confirmed SARS-CoV-2 infection.(6)
- 69 Another recent study showed that time to mounting an anti-S secretory IgA response in the nasal cavity
- 70 correlated significantly with the duration of viral shedding determined by virus culture. However, in that
- study, time to seroconversion and duration of viral shedding were both estimated from models based
- on different study populations. (7) And less is known about the role of mucosal antibody responses in
- oral fluid as a correlate of protection from other aspects of COVID-19 including time to viral clearance
- 74 (first PCR negative test after COVID-19 infection), time to symptom resolution, and risk of developing
- 75 Post COVID Conditions.(8) We sought to determine whether mucosal humoral antibody responses to
- 76 SARS-CoV-2 were associated with viral clearance and symptom resolution. A better understanding of the
- 77 role of mucosal immune responses will help inform intranasal COVID-19 vaccination strategies that
- 78 boost mucosal immunity moving forward and assay standardization and harmonization efforts to assess
- 79 immune responses in different mucosal compartments.(9,10)

80 Methods

81 <u>Study design</u>

- 82 This study assessed oral mucosal SARS-CoV-2 antibody responses in individuals with PCR-confirmed
- 83 SARS-CoV-2 infection who participated in one of two prospective cohort studies, OutSMART (11,12) or
- 84 SEARCh (13,14). The OutSMART study was approved by the Johns Hopkins University School of Medicine
- 85 Institutional Review Board (IRB; IRB00259948). The SEARCh study was approved by the IRB of Johns
- 86 Hopkins University Bloomberg School of Public Health (IRB00014200); the IRB of the Centers for Disease
- 87 Control and Prevention approved the study based on the review of the Johns Hopkins University
- 88 Bloomberg School of Public Health IRB.
- 89 Briefly, OutSMART enrolled predominantly adult participants who were identified through the Johns
- 90 Hopkins Outpatient SARS-CoV-2 testing network and received a positive SARS-CoV-2 RT-PCR result.
- 91 Participants self-collected swabs for SARS-CoV-2 RT-PCR testing and oral fluid for antibody testing and
- 92 provided symptom information on study days 0, 3, 5, 7, 10, 14, 21 and 28. OutSMART samples collected

- between April 23, 2020, and February 22, 2022, contributed to this analysis. The SEARCh study enrolled
- 94 households with at least one child <5 years old to participate in surveillance for incident SARS-CoV-2
- 95 infection for up to 8 months. Participants provided weekly nasal swabs for PCR testing and symptoms
- 96 information and, upon PCR-confirmed SARS-CoV-2 infection, up to eight weekly oral fluid samples.
- 97 SEARCh specimens collected between December 16, 2020, and October 6, 2021, contributed to this
- 98 analysis. More detailed information about the study designs has been published previously and is
- 99 provided in the **Supplement**. (11–14)

100 <u>Oral fluid collection and multiplex SARS-CoV-2 antibody assays</u>

- 101 Oral fluid (Oracol+, Malvern Medical Developments, UK) and nasal swabs for PCR testing were
- 102 participant-collected and mailed to the testing lab. Oral fluid collected 0 to 125 days after infection
- 103 onset was tested for SARS-CoV-2 receptor binding domain (RBD)- and Spike (S)-specific IgG, IgA and
- secretory-component (SC)-containing lg responses using magnetic bead-based multiplex immunoassays
- 105 optimized for oral fluid, as described previously. (15–17) Mucosal SC of polymeric Ig was detected using a
- 106 mouse monoclonal anti-SC antibody, followed by labeled anti-mouse antibody, hereafter referred to as
- secretory IgA (SIgA) since IgA is the predominant secretory Ig in oral fluid.(18) Qualitative thresholds for
- 108 oral fluid anti-S and RBD IgG had been established previously. (16,19) Assay performance for detecting
- anti-S-RBD IgG was 99.4% sensitivity (481/484 correct positives) and 99.3% specificity (995/1002 correct
- negatives) using oral fluid from presumably naïve individuals (~1,000 samples), oral fluid collected >14
- days after completing a COVID-19 vaccination series (~175 samples) and/or >14 days after symptoms
- 112 onset or after the first SARS-CoV-2 RT-PCR positive test (~325 samples).

113 <u>Statistical analysis</u>

- 114 *Time to viral clearance.* SARS-CoV-2 infection onset was defined as participant-reported COVID-19
- symptom start date or the first PCR positive date, whichever occurred earlier. If asymptomatic, the first
- PCR positive date was used. The date of viral clearance was defined as the median date between the last
- 117 SARS-CoV-2 RT-PCR positive and first negative nasal swab if less than 20 days apart.(12) If no first
- negative nasal swab PCR test was available within 20 days after the last positive PCR test, the
- 119 individual's oral fluid samples were excluded from time to clearance analyses. Time to viral clearance in
- 120 days was calculated as the difference between infection onset and date of clearance as defined above.
- 121 *Symptom duration.* Similarly, symptom duration was defined as the difference in days between infection
- onset and the median date between the last day on which any COVID-19 symptoms were reported and
- 123 the first asymptomatic day or, when available, the participant-reported date of symptoms resolution.
- 124 COVID-19 symptoms. Both studies assessed symptoms, however, symptom severity was only assessed in
- 125 OutSMART. COVID-19 symptoms considered here and assessed in both studies included fever and chills,
- sore throat, loss of smell or taste, cough, congestion (nose, sinus pressure), body or muscle aches, chest
- 127 congestion or pain, shortness of breath or difficulty breathing and diarrhea. The number of reported
- 128 COVID-19 symptoms reported was calculated for each participant. In OutSMART the number of
- symptoms of the study visit during which the most COVID-19 symptoms were reported was used. Most
- participants reported the highest number of COVID-19 symptoms at enrollment through study day 3
- 131 (143/204 participants; 71%). SEARCh inquired weekly about onset of COVID-19 and other symptoms. To
- 132 capture COVID-19 symptoms reported within an equivalent time frame, COVID-19 symptoms reported

one week prior and up to two weeks after the first PCR positive test counted towards the number ofCOVID-19 symptoms reported.

- 135 Infecting SARS-CoV-2 variant. If the infecting variant was unknown, the most prevalent variant (20)
- 136 circulating at the time of PCR-confirmed SARS-CoV-2 infection was imputed with wild type imputed for
- 137 infections occurring through February 2021; Alpha from March 2021 instead of April (20) to match the
- sequencing-derived variant results available (SEARCh) through June 2021; Delta from July through
- November 2021; and Omicron starting in December 2021 until study end. This approach resulted in
- 140 matching sequencing-based and imputed SARS-CoV-2 variant strains for all sequencing-confirmed SARS-
- 141 CoV-2 isolates (24/24 isolates in SEARCh and 7/7 confirmed Omicron isolates in OutSMART).
- 142 *Statistical models*. Cox proportional hazard models and Kaplan-Meier survival plots were used to assess
- associations between temporal dynamics of oral fluid SARS-CoV-2 antibody levels and other factors with
- 144 time to viral clearance and COVID-19 symptom resolution. Asymptomatic individuals were assigned a
- symptom duration of 0 days and included in analyses (coded in time to event analyses as 1 = resolution
- of symptoms reached). Oral fluid anti-S antibody responses were classified into tertiles (low, moderate,
- and high), allowing for stratified visualization with Kaplan-Meier survival plots and easier comparison
- 148 with other factors such as prior COVID-19 vaccine immunity. In another approach, participants were
- 149 classified into tertiles based on their median, rather than time-varying, anti-S response post infection
- 150 (low, moderate, high SIgA responder), while maintaining anti-S IgG as a time-varying covariate in the
- 151 model. A third approach used time-stratified analysis to test whether the direction and magnitude of
- associations remained consistent over time.
- 153 In Cox proportional hazard models and in Kaplan-Meier survival analyses the event (viral clearance or
- 154 symptom resolution) was coded as 1. Therefore, in contrast to survival analyses where the event is
- disease or death coded as 1, in the models presented here hazard ratios (HR)>1 indicate higher
- 156 likelihood of viral clearance or symptom resolution and shorter time to clearance or symptom resolution
- 157 in Kaplan-Meier analyses; HRs<0 indicate lower likelihood of and shorter time to clearance or symptom
- resolution. Linear regression models with generalized estimating equations (GEE) were also used to
- estimate the effect of anti-S and anti-RBD SlgA, IgA and IgG responses on time to clearance and
- 160 symptom duration.
- 161 Models were adjusted for COVID-19 vaccination status (received at least 1 COVID-19 vaccine dose versus
- 162 unvaccinated at time of infection), infecting variant, age group (<5, 5-17, >=18, >65 years), sex, race, and
- 163 ethnicity. GEE models were also adjusted for time since infection onset. All models included clustering
- 164 equations to account for non-independence of repeated oral fluid measurements within individual.
- 165 Collinearity between independent covariates was estimated by calculating variance inflation factors for
- all models. Only models with variance inflation factors under 4 are presented here. Analyses were
- 167 performed in R version 4.2.1 using packages tidyverse, survival, survminer, forestploter, adjustedCurves,
- 168 ggpubr, and car.

169 Results

- 170 Oral fluid samples (n=1,256) from 257 adults and children with PCR-confirmed COVID-19 infection who
- 171 participated either in the OutSMART or SEARCh cohort studies were analyzed for anti-RBD and anti-S
- secretory component-containing lg (predominantly secretory lgA [SlgA]), lgA and lgG responses. Almost
- all participants experienced mild or moderate COVID-19 disease; children were more often

- asymptomatic, as described in more detail elsewhere.(11–13) Participant characteristics stratified by
- study cohort and combined are shown in **Table 1**. The median time from infection onset to viral
- 176 clearance, as defined above, was 15 days (interquartile range [IQR] = [9.5; 21.5]) and median time to
- 177 resolution of COVID-19 symptoms was 18 days (IQR = [9.25; 37.0]).
- 178 Factors associated with SARS-CoV-2 clearance and COVID-19 symptom resolution. Higher anti-S SIgA
- 179 level and COVID-19 vaccination status were associated with greater likelihood of viral clearance and
- resolution of symptoms (Figure 1). Moderate compared to low anti-S SIgA was associated with a 1.8-fold
- 181 greater likelihood of viral clearance (adjusted hazard ratio [aHR] with 95% confidence interval [CI] = 1.8
- 182 [1.2-2.5]; p=0.002) and 1.7-fold greater likelihood of COVID-19 symptoms resolution (aHR [95% CI] = 1.7
- 183 [1.2-2.3], *p*=0.003). High compared to low anti-S SIgA was associated with a 2.2-fold and 2.1-fold greater
- 184 likelihood of viral clearance (aHR [95% CI] = 2.2 [1.5-3.1], *p*<0.001) and symptom resolution (aHR [95%
- 185 CI] = 2.1 [1.5-2.9], *p*<0.001), respectively. Prior immunity from COVID-19 vaccination was also associated
- with greater likelihood of clearance (aHR [95% Cl] = 2.5 [1.8-3.4], p<0.001) and resolution of symptoms (aHR [95% Cl] = 1.9 (1.3-2.7], p<0.001). In contrast, higher anti-S lgG was associated with reduced
- 107 (and $[9570 \text{ cl}] = 1.9 (1.9 \cdot 2.7)$, p < 0.001). In contrast, higher anti-5 igo was associated with 199
- 188 likelihood of viral clearance and symptoms resolution (**Figure 1**).
- 189 In children under 5 years of age, higher anti-S SIgA was also associated with increased likelihood of viral
- 190 clearance (aHR [95% CI] for each log_{10} increase in anti-S SlgA = 1.4 [1.0-1.9], p<0.05) and of symptoms
- resolution (aHR [95% CI] for each log₁₀ increase in anti-S SIgA = 1.4 [1.2-1.6] p<0.001). Higher anti-S IgG
- in children was associated with lower likelihood of viral clearance (aHR [95% Cl] for each log₁₀ increase in
- anti-S lgG = 0.6 [0.4-0.9], *p*<0.01; **Tables S1 and S7**). These trends remained consistent and statistically
- significant in independent analyses of both study cohorts (**Tables S2-S3**) and of unvaccinated adults
- 195 (**Table S8**). In the OutSMART cohort, age >65 years was a risk factor for prolonged PCR positivity (aHR
- 196 [95% CI] = 0.6 [0.3-0.9], p<0.05; **Table S3**); the SEARCh cohort did not enroll participants over 65 years.
- 197 In the SEARCh cohort, younger age (children 0-17 years old) was associated with greater likelihood of
- viral clearance (aHR [95% Cl] = 1.35 [1.02-1.80], p<0.05; **Table S4**). Adjusting for the infecting variant did
- 199 not affect the magnitude or direction of these associations significantly but showed that Delta and
- 200 Omicron infections were associated with significantly shorter time to viral clearance than wildtype
- 201 infections (Table S5).
- 202 Differences in time to clearance and symptoms resolution. In Kaplan-Meier survival estimates stratified
- by anti-S SIgA tertile, moderate oral fluid anti-S SIgA compared to low SIgA was associated with clearing
- the virus 10 days earlier (95% CI: 7-14 days) and with becoming asymptomatic 9 days (95% CI: 6-14 days)
- 205 earlier. High compared to low anti-S SIgA was associated with clearing the virus 14 days (95% CI: 10-18
- 206 days) earlier and with becoming asymptomatic 14 days (95%CI: 10-17 days) earlier (**Figure 2**). The
- 207 direction and effect size of these associations remained consistent over time as confirmed with time
- since infection restricted subsets of oral fluid and using participants' median rather than time varying
- SIgA response post infection (see Supplement Time-restricted models and Median SIgA response post
 infection).
- Association of oral fluid anti-RBD Ig with time to clearance and COVID-19 symptoms duration. Mucosal
- 212 SARS-CoV-2 RBD-specific SIgA and IgA in children and adults were higher among the two-thirds of study
- 213 participants (67%) who cleared the virus within 18 days post infection onset compared to those who
- tested PCR positive longer (**Figure S2**). Oral fluid SARS-CoV-2 IgG levels, which correlate with serum
- 215 SARS-CoV-2 IgG levels (16,17), were similar in individuals who cleared the virus in ≤18 days and >18 days

- among adults. The number of children that did not clear the virus within 18 days (n=4) was too small for
- representative comparison of the two groups (**Figure S2**). Adults who resolved symptoms within four
- 218 weeks had significantly higher anti-RBD SIgA and IgA, but not IgG, 15-30 days after infection onset than
- individuals who remained symptomatic longer than four weeks (*p*<0.0001; Figure S3).
- 220 Association between delayed seroconversion and viral clearance. Even though higher anti-S IgG in oral
- fluid was associated with longer time to viral clearance, shorter time to a first positive oral fluid anti-S
- lgG result (shorter time to seroconversion) remained associated with faster viral clearance (**Table S6**), as
- shown previously in a subset of the OutSMART cohort.(12) GEE models estimated a 0.8-day increase
- (beta [SE] = 0.8 [0.2], p<0.001) in time to clearance for each one-day delay in time to anti-S lgG
- 225 seroconversion.
- 226 Linear regression model to estimate associations between oral fluid anti-S and anti-RBD Ig and time to
- 227 SARS-CoV-2 clearance or COVID-19 symptoms duration. Each log₁₀ unit increase in anti-S and anti-RBD
- 228 SIgA and IgA was associated with three to five days faster viral clearance and COVID-19 symptoms
- resolution. Every log₁₀ increase of oral fluid anti-RBD (Sino Biological, China) SIgA was associated with
- beta [SE] -2.7 days [1.3], p<0.05 faster viral clearance; while every log₁₀ increase in anti-S (Mt. Sinai) IgA
- was associated with 3.4 days faster viral clearance (beta [SE]: -3.4 days [1.3]; p<0.01, Table S9). Similarly,
- each log₁₀ increase in oral fluid anti-S-RBD was associated with 3.4 to 4.9 days earlier resolution of
- 233 COVID-19 symptoms (beta [SE]: -3.4 [1.6]; *p*<0.05 to -4.9 [1.9] days, *p*<0.01, **Table S10**). Higher anti-S lgG
- was again associated with longer time to clearance and to becoming asymptomatic. Children cleared the
- virus about one week earlier than adults (beta [SE] = -6.8 days (2.7); p<0.01) and recovered significantly
- faster from COVID-19 symptoms than adults (beta [SE] = -16.5 (2.7); p<0.001), while among adults self-
- reported Black race appeared associated with longer time to clearance and symptoms duration (Table
 S10).
- Lastly, we investigated whether the mucosal immune response to SARS-CoV-2 differed depending on
- the maximum number of COVID-19 symptoms reported (0-3, 4-6, or >6 symptoms). Participants who
- reported experiencing >6 compared to 4-6 and 0-3 COVID-19 symptoms had higher anti-RBD IgG 14-30
- 242 days after infection onset. This trend was consistent among children (Kruskal-Wallis p<0.05) and among
- adults (p<0.01) but anti-RBD IgG <14 days post infection and anti-RBD SIgA or IgA did not appear
- associated with the number of COVDID-19 symptoms reported (**Figure S4**).

245 Discussion

Among children and adults, early and robust mucosal SARS-CoV-2 SIgA and IgA responses in oral fluid 246 247 were associated with faster viral clearance and earlier recovery from COVID-19 symptoms. Early anti-S 248 IgG seroconversion was associated with faster viral clearance, as shown before in the OutSMART cohort 249 (12), while higher anti-S IgG was associated with longer time to clearance and to resolution of COVID-19 250 symptoms. These findings are consistent with prior research showing positive correlations between 251 blood anti-S IgG and nAb titers in convalescence and COVID-19 disease severity and symptoms duration 252 (21–23), and between delayed nAb and anti-S IgG responses and severe outcomes in children and fatal 253 outcomes COVID-19 in adults. (23,24) Our group has also demonstrated that prolonged time to viral 254 clearance during the acute phase of SARS-CoV-2 infection is associated with long COVID.(25) We showed 255 that COVID-19 vaccine-induced immunity at the time of infection was associated with faster clearance 256 and earlier resolution of symptoms with equivalent effect size as moderate and high SIgA. Early, robust 257 anti-S SIgA responses in oral fluid may thus be a correlate for protection from prolonged viral

persistence and from prolonged duration of COVID-19 symptom with comparable magnitude asconferred by intramuscular COVID-19 vaccination.

260 These findings are consistent with a model in which early and robust local mucosal anti-S SIgA and 261 timely IgG seroconversion contribute to early viral clearance, e.g., by blocking viral attachment to 262 mucosal cell surfaces (SARS-CoV-2 binding to ACE2) and thus preventing infection of target epithelial 263 cells and later spread to other sites of infection. In this model, individuals who cannot mount early and 264 robust local mucosal anti-S SIgA responses and/or who experience prolonged time to rise of anti-S IgG 265 are more likely to experience prolonged unmitigated infection, higher virion burden at sites of infection, 266 and/or systemic spread. These individuals would have a higher burden of viral antigen interacting with B 267 cells throughout lymphatic tissue and therefore would be more likely to eventually mount higher titers 268 of anti-SARS-CoV-2 lgG.

- 269 Limitations of this research included that the SEARCh and OutSMART study COVID-19 symptoms
- assessments were not administered at the same time intervals relative to COVID-19 infection and that
- symptom severity was only captured in one of the two cohorts, thus limiting the sample size to
- investigate associations between oral fluid antibody responses and COVID-19 severity. Only the number
- of SARS-CoV-2 symptoms, which were reported in both cohorts, and symptom duration but not
- 274 symptom severity in relation to oral mucosal antibody responses were investigated here.
- 275 We showed that unvaccinated adults who experienced COVID-19 symptoms for more than four weeks
- had significantly lower levels of oral fluid anti-RBD SIgA and IgA than those who resolved symptoms
- 277 earlier. However, we could not assess the role of SIgA in the development of long COVID here. Post
- 278 COVID Conditions, including symptoms such as fatigue, post-exertional malaise, and brain fog that
- 279 persist beyond or start after the four-week COVID-19 symptom duration period, were ascertained in
- 280 only one of the study cohorts and were therefore excluded from this analysis.
- 281 Since in OutSMART PCR measurements were only available on select study days rather than weekly,
- approximately 50 out of 300 potential participants with either missing or delayed first negative PCR tests
- 283 (≥20 days after the last PCR positive test) had to be excluded from time to event analyses. Similarly,
- 284 SEARCh study participants who experienced COVID-19 infection near the end of the study period were
- excluded since date of first PCR negative nasal swab and of symptoms resolution were not ascertained
- and thus time to clearance and symptoms duration could not be calculated. Others modeled the viral
- shedding duration and the time to SIgA seroconversion in nasopharyngeal swabs based on the viral
- dynamics observed in other studies.(7) Here we chose to only include participants for which oral fluid
- antibody measurements were obtained and time to viral clearance (first SARS-CoV-2 PCR negative test)
- and symptoms duration could be calculated.
- 291 Finally, this study used qualitative FDA-EUA-approved SARS-CoV-2 PCR assays to infer time to viral
- 292 clearance rather than SARS-CoV-2 virus culture, which was only available for a subset of PCR-positive
- 293 swabs and originated from different laboratories. Therefore, the time to viral clearance used in this
- analysis represents the time from participant-reported symptoms onset or first PCR positive test to the
- first SARS-CoV-2 PCR negative test and is likely longer than the SARS-CoV-2 transmission window during
- which infectious virus is shed.
- A Swedish study of COVID-19 vaccinated healthcare workers found that high post-vaccination SARS-CoV-
- 298 2 specific SIgA levels may protect from SARS-CoV-2 breakthrough infections and recent research showed

- that the model-inferred duration of viral shedding duration was reduced when estimated nasal anti-S
- 300 SIgA seroconversion occurred earlier. (5,7) Taken together, these studies and our research indicate that
- 301 vaccine strategies that boost mucosal humoral immune responses, such as intranasal or inhaled SARS-
- 302 CoV-2 vaccines known to boost S-RBD-binding local SlgA, may help protect from breakthrough SARS-
- CoV-2 infection, reduce the window for transmission, and reduce the duration and severity of COVID-19
- 304 symptoms following infection.(9,10,26) These findings underscore the importance of measures of
- 305 mucosal immunogenicity, particularly standardization and harmonization as large-scale mucosal
- 306 vaccination efforts such as Project NextGen proceed.
- Future studies should investigate if mucosal anti-S SIgA could be a mechanistic (i.e., causal) or
- 308 nonmechanistic correlate (i.e., associated, but not the primary mechanistic cause) (27,28) for faster viral
- 309 clearance and resolution of COVID-19 symptoms. Mucosal secretory antibody responses are among
- 310 several immune functions that could contribute to effective clearance of SARS-CoV-2 in addition to
- innate immune responses and other adaptive immune responses including antigen-specific killing of
- 312 infected cells by CD8⁺ T cells.(29) Our work indicates a role for SIgA in clearance of virus and resolution
- of symptoms. Future work should focus on whether mucosal anti-S/RBD SIgA responses during acute
- 314 SARS-CoV-2 infection are associated with later development of Post COVID Conditions, which include
- the persistence of COVID-19 symptoms, recurrence, or development of new symptoms four of more
- 316 weeks after an initial SARS-CoV-2 infection.(30)

317 Funding

- Funding for this study was provided by the Johns Hopkins COVID-19 Research Response Program and
- 319 the FIA Foundation. N.P., K.K., and C.D.H. were supported by a gift from the GRACE Communications
- Foundation. C.D.H., N.P., and B.D. were additionally supported by the National Institute of Allergy and
- 321 Infectious Diseases (NIAID) grants R21AI139784 and R43AI141265 and the National Institute of
- 322 Environmental Health Sciences (NIEHS) grant R01ES026973. C.D.H. was also supported by NIAID grant
- R01Al130066 and R01ES026973. C.D.H. was also supported by NIH. grant U24OD023382. YM received
- 324 support for this work from the Henry M. Jackson Foundation for the Advancement of Military Medicine
- 325 (contract number 1007957) and the Sherrilyn and Ken Fisher Center for Environmental Infectious
- 326 Diseases Discovery Program. AA is supported by the National Institutes of Health (grant number
- 327 K08Al143391). This work was supported by the Sherrilyn and Ken Fisher Center for Environmental
- 328 Infectious Diseases Discovery Program and the Johns Hopkins University School of Medicine COVID-19
- Research Fund. Y.C.M. received salary support from the National Institutes of Health (grant numbers
- 330 U54EB007958–12, U5411090366, U54HL143541-02S2, UM1Al068613). The SEARCh study was funded by
- the Centers for Disease Control and Prevention, grant number 75D30120C08737.

Participant characteristic	OutSMART	SEARCh	Combined
Participants, n	208	49	257
Prior Immunity			
Vaccinated against COVID-19, n (%)	38 (18%)	4 (8%)	42 (16%)
Not COVID-19 vaccinated, n (%)	170 (82%)	45 (92%)	215 (84%)
Sex			
Female	124 (60%)	23 (47%)	147 (57%)
Male	84 (40%)	26 (53%)	110 (43%)
Age Group			
0-4 years, n (%)	3 (1%)	19 (39%)	22 (9%)
5-17 years, n (%)	7 (3%)	11 (22%)	18 (7%)
>=18 years, n (%)	167 (80%)	19 (39%)	186 (72%)
>65 years, n (%)	31 (15%)	0 (0%)	31 (12%)
Race / Ethnicity			
White, non-Hispanic	94 (45%)	35 (71%)	129 (50%)
Black, non-Hispanic	74 (36%)	1 (2%)	75 (29%)
Multiracial, non-Hispanic	12 (6%)	9 (18%)	21 (8%)
Hispanic	28 (13%)	1 (2%)	29 (11%)
SARS-CoV-2 Variant			
Wildtype	136 (65%)	18 (37%)	154 (60%)
Alpha	41 (20%)	18 (37%)	59 (23%)
Delta	21 (10%)	13 (26%)	34 (13%)
Omicron	10 (5%)	0 (0%)	10 (4%)
Days to viral clearance, median (IQR)	15.5 (12 - 23.5)	10.5 (7.5-16.5)	15 (9.5 - 21.5)
Days to COVID-19 symptoms resolution,			
median (IQR)	25 (13.5 - 25)	5 (0 - 10)	18 (9.25-37)
Days to first oral fluid collection after			
symptoms onset or first SARS-CoV-2			
positive PCR if asymptomatic, median (IQR)	9 (5 – 16.5)	7 (5 – 9)	8 (5 – 13)
Days to oral fluid collection, median (IQR)*	18 (11 – 34)	33.5 (15 – 55)	22 (12 – 43)
Oral fluid samples, n	838	418	1256

332 **Table 1.** Participant characteristics by study cohort

333 Note: IQR = interquartile range (25%ile – 75%ile). *Oral fluid was collected weekly (SEARCh) after SARS-

334 CoV-2 PCR positive test or on study days 0, 3, 5, 7, 10, 14, 21, 28 (OutSMART).

335 A. SARS-CoV-2 clearance.

Factors assessed	Subgroup	n (%)	aHR (95% CI)		p-value
anti-Spike SC-lg (SIgA)	Low SIgA	175 (33.5)		1	
	Moderate SIgA	174 (33.3)	1.75 (1.23-2.47)	⊢ ⊷−1	0.002
	High SIgA	174 (33.3)	2.19 (1.54-3.12)	⊢ ← →	<0.001
anti-Spike IgG	Low IgG	325 (33.3)			
	Moderate IgG	325 (33.3)	0.69 (0.48-0.99)	H+	0.044
	High IgG	325 (33.3)	0.52 (0.35-0.76)	He-I	0.001
COVID-19 vaccination	Unvaccinated	782 (80.0)		į	
	Vaccinated	195 (20.0)	2.49 (1.82-3.43)	· · · · · · · · · · · · · · · · · · ·	<0.001
Gender	Female	501 (51.3)		į	
	Male	476 (48.7)	1.10 (0.92-1.30)	H e -I	0.303
Age Group	>=18 years	711 (72.8)			
	0-17 years	266 (27.2)	1.16 (0.89-1.52)	H o -i	0.265
Race / Ethnicity	White, non-Hispanic	585 (59.9)		i	
	Black, non-Hispanic	199 (20.4)	0.72 (0.46-1.12)	H.	0.144
	Asian, non-Hispanic	30 (3.1)	0.77 (0.65-0.91)	- Hel	0.002
	Multiracial, non-Hispanic	73 (7.5)	1.36 (1.04-1.79)		0.027
	Hispanic	90 (9.2)	0.78 (0.44-1.38)		0.388
			(0 1 2 3	

Lower likelihood of Higher likelihood of SARS-CoV-2 clearance SARS-CoV-2 clearance

336

337 B. COVID-19 symptom resolution.

Factors assessed	Subgroup	n (%)	aHR (95% CI)		p-value
anti-Spike SC-lg (SIgA)	Low SIgA	199 (33.3)			
	Moderate SIgA	199 (33.3)	1.65 (1.19-2.28)	H-	0.003
	High SIgA	199 (33.3)	2.08 (1.51-2.87)	⊢ ♦−−1	<0.001
anti-Spike IgG	Low	405 (33.4)			
	Moderate	405 (33.4)	0.61 (0.46-0.81)	Het .	0.001
	High	404 (33.3)	0.42 (0.30-0.58)	101	<0.001
COVID-19 vaccination	Unvaccinated	1011 (83.1)		i	
	Vaccinated	205 (16.9)	1.90 (1.34-2.69)		<0.001
Gender	Female	651 (53.5)			
	Male	565 (46.5)	1.12 (0.93-1.35)	HD-1	0.235
Age Group	>=18 years	940 (77.3)			
	0-17 years	276 (22.7)	1.25 (0.97-1.60)	H 4 -1	0.084
Race / Ethnicity	White, non-Hispanic	687 (56.5)			
	Black, non-Hispanic	297 (24.4)	0.73 (0.51-1.04)	H H	0.085
	Asian, non-Hispanic	30 (2.5)	0.93 (0.74-1.17)	H	0.548
	Multiracial, non-Hispanic	84 (6.9)	1.53 (0.98-2.40)	•	0.062
	Hispanic	118 (9.7)	0.77 (0.46-1.28)	He I	0.308
				0 1 2 3	

Lower likelihood of COVID-19 Higher likelihood of COVID-19 symptoms resolution symptoms resolution

- 339 Figure 1. Cox proportional hazard model to assess factors associated with A. SARS-CoV-2 clearance (first
- 340 SARS-CoV-2 PCR negative test) and **B.** COVID-19 symptom resolution. **Note:** aHR = hazard ratio
- 341 estimated from Cox proportional hazard model adjusted for all covariates presented in the table and
- 342 clustered at the individual level. CI = Confidence interval. SC = Secretory component. In time to event
- analyses 1 = time individual (A) clears the SARS-CoV-2 virus (tests SARS-CoV-2 PCR negative), or (B)
- reports being asymptomatic; 0 = individual continues to (A) test SARS-CoV-2 PCR positive, or (B) report
- 345 COVID-19 symptoms. HRs > 1.0 indicate higher likelihood and HRs < 1.0 indicate lower likelihood of (A)
- 346 SARS-CoV-2 clearance, or (**B**) resolution of COVID-19 symptoms.



347

Figure 2. Kaplan-Meier survival curves stratified by oral fluid anti-spike SIgA response post COVID-19

symptoms onset (low; moderate and high SIgA tertile). **A**. Probability of testing SARS-CoV-2 PCR positive

over time in days. **B**. Probability of persisting COVID-19 symptoms over time in days.

351 References

- Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Severity and Outcomes of SARS-CoV-2 Reinfection
 Compared with Primary Infection: A Systematic Review and Meta-Analysis. Int J Environ Res
 Public Health. 2023 Feb 1;20(4).
- Suleyman G, Fadel R, Patel K, Shadid AM, Stuart HBC, Kattula M, et al. Outcomes associated with
 SARS-CoV-2 reinfection in individuals with natural and hybrid immunity. J Infect Public Health
 [Internet]. 2023 Aug 1 [cited 2024 Jan 11];16(8):1262–8. Available from:
- 358 https://pubmed.ncbi.nlm.nih.gov/37302273/
- Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained A
 Correlate of Protection for Vaccines. N Engl J Med. 2022 Dec 15;387(24):2203–6.
- Becerra X, Jha A. Project NextGen Defeating SARS-CoV-2 and Preparing for the Next Pandemic.
 New England Journal of Medicine [Internet]. 2023 Aug 31 [cited 2024 Feb 18];389(9):773–5.
 Available from: https://www.nejm.org/doi/full/10.1056/NEJMp2307867
- Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, et al. Anti-Spike
 Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. N Engl J Med [Internet]. 2022 Oct
 [cited 2023 Apr 4];387(14):1333–6. Available from: /pmc/articles/PMC9511632/
- Fröberg J, Gillard J, Philipsen R, Lanke K, Rust J, van Tuijl D, et al. SARS-CoV-2 mucosal antibody
 development and persistence and their relation to viral load and COVID-19 symptoms. Nat
 Commun [Internet]. 2021 Dec 1 [cited 2023 Sep 5];12(1). Available from:
 /pmc/articles/PMC8460778/
- Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, et al. Infectious virus shedding
 duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.
 Proceedings of the National Academy of Sciences [Internet]. 2023 Dec 22 [cited 2024 Jan
- 374 2];120(52):e2314808120. Available from:
- 375 https://www.pnas.org/doi/abs/10.1073/pnas.2314808120
- Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Vol. 21, Nature
 Reviews Microbiology. Nature Publishing Group; 2023. p. 147–61.
- McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann NP, et al. Mucosal boosting
 enhances vaccine protection against SARS-CoV-2 in macaques. Nature 2023 [Internet]. 2023 Dec
 14 [cited 2024 Jan 11];1–3. Available from: https://www.nature.com/articles/s41586-023-069513
- 38210.Knisely JM, Buyon LE, Mandt R, Farkas R, Balasingam S, Bok K, et al. Mucosal vaccines for SARS-383CoV-2: scientific gaps and opportunities-workshop report. NPJ Vaccines [Internet]. 2023 Dec 1384[cited 2024 Jan 11];8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/37045860/
- Blair PW, Brown DM, Jang M, Antar AAR, Keruly JC, Bachu VS, et al. The Clinical Course of COVID19 in the Outpatient Setting: A Prospective Cohort Study. Open Forum Infect Dis. 2021 Feb 1;8(2).
- Antar AAR, Yu T, Pisanic N, Azamfirei R, Tornheim JA, Brown DM, et al. Delayed Rise of Oral Fluid
 Antibodies, Elevated BMI, and Absence of Early Fever Correlate with Longer Time to SARS-CoV-2

389 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. Open Forum Infect 390 Dis. 2021 Jun 1;8(6). 391 13. Karron RA, Hetrich MK, Na Y Bin, Knoll MD, Schappell E, Meece J, et al. Assessment of Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children Aged 0 to 4 Years and Their 392 393 Household Members. JAMA Netw Open [Internet]. 2022 Aug 1 [cited 2023 Apr 4];5(8):e2227348-394 e2227348. Available from: 395 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2795801 396 14. Dawood FS, Couture A, Zhang X, Stockwell MS, Porucznik CA, Stanford JB, et al. Severe Acute 397 Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Responses After Community 398 Infections in Children and Adults. Open Forum Infect Dis [Internet]. 2023 May 3 [cited 2023 Sep 399 12];10(5). Available from: https://dx.doi.org/10.1093/ofid/ofad168 400 15. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19 serology at 401 population scale: SARS-CoV-2-specific antibody responses in saliva. J Clin Microbiol. 2021 Jan 402 1;59(1). 403 16. Pisanic N, Antar AAR, Kruczynski KL, Gregory Rivera M, Dhakal S, Spicer K, et al. Methodological 404 approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation 405 with serologic and neutralizing antibody responses. J Immunol Methods. 2023 Mar 1;514. 406 17. Heaney CD, Pisanic N, Randad PR, Kruczynski K, Howard T, Zhu X, et al. Comparative performance 407 of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and 408 neutralization titers. Journal of Clinical Virology. 2021 Dec 1;145. 409 18. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral Microbiol. 410 2013;5(2013):1-24. 411 19. Gigot C, Pisanic N, Kruczynski K, Gregory Rivera M, Spicer K, Kurowski KM, et al. SARS-CoV-2 412 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022. mSphere. 2023 Feb 21;8(1). 413 414 20. Quintero AM, Eisner M, Sayegh R, Wright T, Ramilo O, Leber AL, et al. Differences in SARS-CoV-2 415 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant -416 Volume 28, Number 11—November 2022 - Emerging Infectious Diseases journal - CDC. Emerg 417 Infect Dis [Internet]. 2022 Nov 1 [cited 2023 Nov 7];28(11):2270–80. Available from: https://wwwnc.cdc.gov/eid/article/28/11/22-0577 article 418 419 21. Sejdic A, Frische A, Jørgensen CS, Rasmussen LD, Trebbien R, Dungu A, et al. High titers of 420 neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with 421 increased severity in COVID-19 hospitalized patients. Virol J [Internet]. 2023 Dec 1 [cited 2023] 422 Nov 8];20(1):1–12. Available from: 423 https://virologyj.biomedcentral.com/articles/10.1186/s12985-023-01974-8 424 22. Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduction and Targeted Therapy 2020 5:1 425 426 [Internet]. 2020 Sep 2 [cited 2023 Nov 8];5(1):1–6. Available from: 427 https://www.nature.com/articles/s41392-020-00301-9

428 429 430	23.	Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat Med [Internet]. 2021 Jul 1 [cited 2023 Nov 8];27(7):1178–86. Available from: https://pubmed.ncbi.nlm.nih.gov/33953384/
431 432 433	24.	Sananez I, Raiden SC, Algieri SC, Uranga M, Grisolía NA, Filippo D, et al. A poor and delayed anti- SARS-CoV2 IgG response is associated to severe COVID-19 in children. EBioMedicine [Internet]. 2021 Oct 1 [cited 2023 Nov 8];72:103615. Available from: /pmc/articles/PMC8502533/
434 435 436	25.	Antar AAR, Yu T, Demko ZO, Hu C, Tornheim JA, Blair PW, et al. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol. 2023 Apr 28;14:1147549.
437 438 439 440	26.	Hempel H, Mantis N, Heaney CD, Pinto LA. The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop. Hum Vaccin Immunother [Internet]. 2023 Aug 1 [cited 2023 Sep 12];19(2). Available from: https://www.tandfonline.com/doi/full/10.1080/21645515.2023.2253598
441 442 443	27.	Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. N Engl J Med [Internet]. 2022 Dec 15 [cited 2023 Apr 4];387(24):2203–6. Available from: https://pubmed.ncbi.nlm.nih.gov/36507702/
444 445 446	28.	Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis [Internet]. 2012 Jun 1 [cited 2024 Jan 2];54(11):1615–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22437237/
447 448 449	29.	Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity [Internet]. 2022 May 10 [cited 2024 Jan 2];55(5):749–80. Available from: http://www.cell.com/article/S1074761322001844/fulltext
450 451 452	30.	Post-COVID Conditions: Information for Healthcare Providers [Internet]. [cited 2024 Jan 11]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid- conditions.html
453		